Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tonlamarsen in Uncontrolled Hypertension
NCT05314439Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Jan 2023
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of tonlamarsen in hypertension (HTN), sponsored by Ionis Pharmaceuticals. Started Apr 2022; status: completed.
02
Drugs
tonlamarsen
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05314439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05314439.